Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate
Open Access
- 9 April 2025
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2490078
Abstract
Receptor tyrosine kinase-like orphan receptor (ROR2) has been identified as a highly relevant tumor-associated antigen in a variety of cancer indications of high unmet medical need, including melanoma, renal cell carcinoma, osteosarcoma, gastrointestinal stromal tumor, colorectal cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer. Overexpression of ROR2 often correlates with advanced disease or poor prognosis, making it an attractive target for cancer therapy. We developed a novel, conditionally active biologic (CAB) antibody-drug conjugate (ADC), ozuriftamab vedotin (BA3021), which binds to ROR2 only in the acidic tumor microenvironment. In healthy tissue, binding to ROR2 is greatly reduced by a novel selection mechanism using physiological chemicals as protein-associated chemical switches (PaCS). The CAB anti-ROR2 ADC displays the anticipated binding properties and mediates potent lysis of ROR2-positive cancer cell lines. In vivo, BA3021 has potent and durable antitumor activity in human cancer xenograft mouse models, including patient-derived xenograft models. In non-human primates, BA3021 was well tolerated at doses of up to 10 mg/kg and showed excellent stability in vivo. These preclinical results indicate that CAB anti-ROR2 ADC is efficacious and well tolerated and may be a promising treatment for cancer patients with ROR2-expressing tumors.Keywords
This publication has 44 references indexed in Scilit:
- WNT5A Expression Increases during Melanoma Progression and Correlates with OutcomeClinical Cancer Research, 2008
- Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2Genes to Cells, 2007
- The receptor tyrosine kinase Ror2 is involved in non‐canonical Wnt5a/JNK signalling pathwayGenes to Cells, 2003
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- Expression and Function of the Ror‐Family Receptor Tyrosine Kinases During Development: Lessons from Genetic Analyses of Nematodes, Mice, and HumansJournal of Receptors and Signal Transduction, 2003
- Loss of mRor1 Enhances the Heart and Skeletal Abnormalities in mRor2-Deficient Mice: Redundant and Pleiotropic Functions of mRor1 and mRor2 Receptor Tyrosine KinasesMolecular and Cellular Biology, 2001
- Distinct Mutations in the Receptor Tyrosine Kinase Gene ROR2 Cause Brachydactyly Type BThe American Journal of Human Genetics, 2000
- Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2Nature Genetics, 2000
- Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formationGenes to Cells, 2000
- A novel family of cell surface receptors with tyrosine kinase-like domain.Journal of Biological Chemistry, 1992